Abstract
On initial reflection, consideration of beta-blockade in the therapy of heart failure (HF) patients seems paradoxical. In most discussions of the therapeutics of congestive heart failure, beta-blockers are listed as contraindicated, given their known negative inotropic potential. The general perception that beta-blockers are contraindicated is adequately supported by clinical anecdotes, in which the administration of beta-blocker therapy (usually intravenously) in patients with acute or subacute and medically uncompensated HF has led to dramatic adverse reactions such as acute pulmonary edema and low output syndrome with hypotension and shock. Thus, the consideration of beta-blockade for therapy of HF patients would appear heretical based on conventional medical wisdom. Nevertheless, standard therapy for HF, while controlling symptoms in the short term, appears to have had little impact on the dismal natural history of the disease (1–4). Given this poor prognosis, the testing of new and unconventional approaches to chronic HF is appropriate. In this regard, it is of interest that despite the obvious danger in administering intravenous and full-dose beta-blocking drugs in acute HF, giving carefully titrated oral doses to patients with medically compensated, chronic HF is gaining increasing clinical and experimental support.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Smith SM. Epidemiology of congestive heart failure. Am J Cardiol 1985;55:3A.
Franciosa JA, Wilen M, Zieschi S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1983;57:831.
Fuster V, Gersh BJ, Biuliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525.
Furberg CD, Yusuf D, Thorn TJ. Potential for altering the natural history of congestive heart failure: need for large clinical trials. Am J Cardiol 1985;55:45A.
Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801.
Beta-Blocker Heart Attack Study Group. The beta-blocker heart attack trial. JAMA 1981;246:2073.
Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981; 2:82.
Hansteen V, Moinichen E, Lorentsen E, et al. One year’s treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Br Med J 1982;284:155.
Pedersen TR. The Norwegian multicenter study of timolol after myocardial infarction. Circulation 1983;67: 1–49.
Rodda BI. The timolol myocardial infarction study: an evaluation of selected variables. Circulation 1983;67: 1–53.
Beta-Blocker Heart Attack Study Group. A randomized trial of propranolol in patients with acute myocardial infarction: mortality results. JAMA 1982;247:1701.
Furberg CD, Byington RP. What do the subgroup analyses reveal about differential exposure to beta-blocker therapy? Circulation 1983;67:1–98.
Goldstein S. Propranolol therapy in patients with acute myocardial infarction: the beta-blocker heart attack trial. Circulation 1983;67:1–53.
Furberg CD, Hawkins CM, Lichstein E. Effect of propranolol in postinfarction patients with mechanical or electrical complications. Circulation 1984;69:761.
Chadda K, Goldstein S, Byington S, et al. The effect of propranolol therapy following acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503.
Hansteen V. Beta blockade after myocardial infarction: the Norwegian Propranolol Study in high-risk patients. Circulation 1983;67(part 2):1–53.
Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022.
Swedberg K, Hjalmarson A, Waagstein F, Wallentin L. Beneficial effects of long-term beta blockade in congestive cardiomyopathy. Br Heart J 1980;44:117.
Swedberg K, Waagstein F, Hjalmarson A, et al. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J 1980;44:134.
Waagstein F, Hjalmarson A, Swedberg K, et al. Beta blockers in dilated cardiomyopathies: they work. Eur Heart J 1983;4(suppl A):173.
Swedberg K, Waagstein F, Hjalmarson A, et al. Prolongation of survival in congestive cardiomypathy by beta-receptor blockade. Lancet 1979;1:1374.
Ikram H, Fitzpatrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet 1981;2:490.
Currie PJ, Kelly MJ, McKenzie A, et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol 1984;3:203.
Weber KT, Likoff MJ, McCarthy D. Low-dose beta blockade in the treatment of chronic cardiac failure. Am Heart J 1982;104:877.
Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985;55:471.
Engelmeier RS, O’Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomypathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536.
Engelmeier R, O’Connell J, Rad N, et al. Metoprolol in dilated cardiomyopathy: long-term follow-up. Circulation 1986;74:II-309.
Fowler MB, Bristow MR, Laser JA, et al. Beta-blocker therapy in severe heart failure: improvement related to beta-1-adrenergic receptor up regulation? Circulation 1984;70:11–112.
Bristow MR. The adrenergic nervous system in heart failure. N Engl J Med 1984;31:850.
Francis GP, Goldsmith SR, Levine TB, et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101:370.
Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819.
Shanes J, Kasabali B, Blend M. Beta-adrenergic blockade in heart failure: potential mechanisms of action. Heart Failure 1986;2:138.
Cryer PE. Physiology and pathophysiology of the human sympathoadrenal neuroendocrine system. N Engl J Med 1980;303:436.
Kline I. Myocardial alterations associated with pheochromocy-tomas. Am J Pathol 1961;38:539.
Opie LH. Effects of catecholamines on normal myocardium: implications for the failing heart. Heart Failure 1986;2:104.
Bristow M, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med 1982;307:205.
Ginsburg R, Bristow MR, Billingham ME, et al. Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am Heart J 1983;106:535.
Chidsey CA, Braunwald E, Morrow AG, et al. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med 1965;39:442.
Covell JW, Chidsey CA, Braunwald E. Reduction of the cardiac response to postganglionic sympathetic nerve stimulation in experimental heart failure. Circ Res 1966;19:51.
Alderman J, Grossman W. Are beta-adrenergic-blocking drugs useful in the treatment of dilated cardiomyopathy? Circulation 1985;71:854.
Anderson JL, Rodier HE, Green LS. Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 1983;51:1196.
Anastasiou-Nana M, Nanas J, Menlove RL, et al. Experimental antifibrillatory effects of calcium channel blockade with diltiazem: comparison with beta blockade and nitroglycerin. J Cardiovasc Pharmacol 1984;6:780.
Schwartz PJ, Yanoli E, Zaza A, et al. The effect of antiarrhythmic drugs on life-threatening arrhythmias induced by interaction between acute myocardial ischemia and sympathetic hyperactivity. Am Heart J 1985;109:937.
Patterson E, Holland K, Eller BT, et al. Ventricular fibrillation resulting from ischemia at a site remote from previous myocardial infarction: a conscious canine model of sudden coronary death. Am J Cardiol 1982;50:1414.
Patterson E, Lucchesi BR. Antifibrillatory actions of d,l-nadolol in a conscious canine model of sudden coronary death. J Cardiovasc Pharmacol 1983;5:737.
Goldstein S, Landis JR, Leighton R, et al. Characteristics of the resuscitated out-of-hospital cardiac arrest victim with coronary heart disease. Circulation 1981;64:977.
Goldstein S, Landis JR, Leighton R, et al. Predictive survival models for resuscitated victims of out-of-hospital cardiac arrest with coronary heart disease. Circulation 1985;71:873.
Holmes DR, Davis KBV, Mock MB, and Participants in the Coronary Artery Surgery Study. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: a report from the Coronary Artery Surgery Study. Circulation 1986;73:1254.
Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. Am J Cardiol 1983;52:32C.
Impact Research Group. International mexiletine and placebo antiarrhythmic coronary trial. I. Report on arrhythmias and other findings. J Am Coll Cardiol 1984;4:1148.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Anderson, J.L. (1987). Is There a Role for Beta-Blockers in Heart Failure Patients?. In: Morganroth, J., Moore, E.N. (eds) Congestive Heart Failure. Developments in Cardiovascular Medicine, vol 75. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2077-7_16
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2077-7_16
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9232-6
Online ISBN: 978-1-4613-2077-7
eBook Packages: Springer Book Archive